Tags: Chemical Compound, Chemical Substance.
BRL-32872 is an experimental drug candidate that provides a novel approach to the treatment of cardiac arrhythmia. Being a derivative of verapamil it possesses the ability to inhibit Ca+2 membrane channels. Specific modifications in hydrogen bonding activity nitrogen lone pair availability and molecular flexibility allow BRL-32872 to inhibit K+ channels as well. As such BRL-32872 is classified as both a class III (K+ blocking) and class IV (Ca+2 blocking) antiarrhythmic agent.
